Two sets of numbers shows how far biopharma activity has progressed in Asia recently. The value of biotech venture capital funding during the first quarter zoomed to $174 million in the first quarter from $150 million in Q4 2015 and a mere $9.4 million in Q1 2015, according to Tech In Asia.
But as the news outlet acknowledges, biotech accounts for a small fraction of total VC funding. The best guess of how small comes from KPMG and CB Insights, whose most recent quarterly Venture Pulse report included biotech within a “healthcare” sector that accounted for 5% of Q1 2016 deals, unchanged from the previous quarter and the year-ago quarter.
